Medicine:Oncofertility
Oncofertility is a subfield that bridges oncology and reproductive research to support fertility preservation in cancer survivors. Cancer treatments, such as chemotherapy, radiation, and surgery, may reduce or destroy a person's ability to have children later in life. Oncofertility also encompasses reproductive issues after cancer treatment, such as family planning, complex contraception, hormonal management throughout survivorship, surrogacy, and adoption. As of 2024[update], oncofertility services are available in most countries outside of Africa.[1]
About 10% of people being treated for cancer are younger than age 40 at the time of diagnosis. As cancer death rates decrease, the preservation of fertility in younger people becomes important to their post-treatment life plans. Preserving fertility prior to cancer treatment can provide hope at the time of diagnosis for families.
Fertility options for men
Established fertility preservation options for men include sperm banking, in which a semen sample is produced, frozen, and stored for future use,[2] and testicular sperm extraction, during which sperm is retrieved directly from the testes through a short surgical procedure and frozen. Experimental options include testicular tissue banking, in which testicular tissue is surgically removed and frozen.[1]
Frozen sperm can be discarded if fertility resumes after treatment.[1] About 10% of adult men who attempt to bank sperm are already infertile.[1]
Fertility options for women
Options for women to have children after cancer have increased significantly in recent years.[3] Women should be counseled on established options such as embryo banking in which hormonal stimulation causes the production of multiple eggs, which are removed, fertilized by sperm, and frozen for future use.
Egg banking is a process of extracting and freezing unfertilized eggs.[4] It uses hormonal stimulation to trigger the production of multiple eggs, which are surgically removed and frozen for storage and future use. The success rate for is lower than most women expect, requiring, on average, about 10 frozen eggs to be used for each live birth.[4]
For radiation, ovarian transposition (surgically moving the ovaries to a different part of the body) and ovarian shielding (physically shielding the ovaries from the area receiving radiation) may be used.[5]
After sterilizing cancer treatment, permanent damage to the uterus could be sustained.[6] A woman can also choose surrogacy (when a woman carries a pregnancy for another woman or couple) or adoption.
Fertility options for children
Prepubescent children have fewer options to preserve fertility than adults.[7] These include testicular sperm extraction for males and ovarian tissue banking for females.
Financial, ethical, and legal considerations
Fertility preservation costs may be high for young patients, and multiple organizations now provide methods to reduce costs for patients.[8] For example, depending on how a country handles healthcare costs and health insurance, the cancer survivor may have to pay directly for the cost of storing frozen sperm.[1]
The Supreme Court of the United States addressed the Social Security implications of oncofertility in March 2012 with Astrue v. Capato.
Research also investigates ethical issues in oncofertility, such as the decision-making process for adolescent children and their families.[9]
Name
The name was coined in 2006 by Teresa K. Woodruff of the Oncofertility Consortium.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Li, Qing; Lan, Qiong-Yu; Zhu, Wen-Bing; Fan, Li-Qing; Huang, Chuan (2024). "Fertility preservation in adult male patients with cancer: a systematic review and meta-analysis". Human Reproduction Open 2024 (1). doi:10.1093/hropen/hoae006. ISSN 2399-3529. PMID 38389980.
- ↑ Sheth, Kunj R.; Sharma, Vidit; Helfand, Brian T.; Cashy, John; Smith, Kristin; Hedges, Jason C.; Köhler, Tobias S.; Woodruff, Teresa K. et al. (2012). "Improved Fertility Preservation Care for Male Patients with Cancer After Establishment of Formalized Oncofertility Program". The Journal of Urology 187 (3): 979–86. doi:10.1016/j.juro.2011.10.154. PMID 22264454.
- ↑ Noyes, Nicole; Knopman, Jaime M.; Long, Kara; Coletta, Jaclyn M.; Abu-Rustum, Nadeem R. (2011). "Fertility considerations in the management of gynecologic malignancies". Gynecologic Oncology 120 (3): 326–33. doi:10.1016/j.ygyno.2010.09.012. PMID 20943258.
- ↑ 4.0 4.1 Fuchs Weizman, N.; Baram, S.; Montbriand, J.; Librach, C. L. (May 2021). "Planned oocyte cryopreservation (Planned OC): systematic review and meta-analysis of cost-efficiency and patients' perspective". BJOG: An International Journal of Obstetrics and Gynaecology 128 (6): 950–962. doi:10.1111/1471-0528.16555. ISSN 1471-0528. PMID 33021076.
- ↑ Jungheim, Emily S.; Carson, Kenneth R.; Brown, Douglas (2010). "Counseling and Consenting Women with Cancer on Their Oncofertility Options: A Clinical Perspective". Oncofertility. Cancer Treatment and Research. 156. pp. 403–12. doi:10.1007/978-1-4419-6518-9_31. ISBN 978-1-4419-6517-2.
- ↑ Griffiths M, Marshall S, Cousins F, Alesi L, Higgins J, Giridharan S, Sarma U, Menkhorst E, Zhou W, Care A, Donoghue J, Holdsworth-Carson S, Rogers P, Dimitriadis E, Gargett C ,Robertson S, Winship A & Hutt K. Radiotherapy exposure directly damages the uterus and causes pregnancy loss. (2023) JCI Insight. 8(6):e163704. doi: 10.1172/jci.insight.163704. PMID 36946464 [1]
- ↑ Wallace, W. Hamish B. (2011). "Oncofertility and preservation of reproductive capacity in children and young adults". Cancer 117 (10 Suppl): 2301–10. doi:10.1002/cncr.26045. PMID 21523750.
- ↑ King, Rosalind Berkowitz (2010). "Perspectives on Oncofertility from Demography and Economics". Oncofertility. Cancer Treatment and Research. 156. pp. 371–9. doi:10.1007/978-1-4419-6518-9_28. ISBN 978-1-4419-6517-2.
- ↑ Galvin, Kathleen M.; Clayman, Marla L. (2010). "Whose Future Is It? Ethical Family Decision Making About Daughters' Treatment in the Oncofertility Context". Oncofertility. Cancer Treatment and Research. 156. pp. 429–45. doi:10.1007/978-1-4419-6518-9_33. ISBN 978-1-4419-6517-2.
 |  |
